SCHEMBL183245

SCHEMBL183245

COc1ccc(-c2ccc3ncnc(-c4cccs4)c3c2)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 2/20 0.60
PIK3CD O00329 5/20 0.57
PIK3CA P42336 5/20 0.57
PIK3CB P42338 5/20 0.57
PIK3CG P48736 5/20 0.57
MTOR P42345 1/20 0.57
ADK P55263 3/20 0.56
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 5/20 0.53
HPGD P15428 4/20 0.53
MAPT P10636 4/20 0.53
HTT P42858 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
LMNA P02545 2/20 0.53
POLB P06746 1/20 0.53
PPARG P37231 1/20 0.53
NCOA2 Q15596 1/20 0.53
NCOA1 Q15788 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182899 0.83 PIK3CD (0.52) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL182771 0.83 PIK3CD (0.73) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL182889 0.82 PIK3CD (0.67) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL182794 0.81 PIK3CD (0.70) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL182765 0.80 PIK3CD (0.69) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL182982 0.79 PIK3CD (0.61) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL183087 0.79 PIK3CD (0.58) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL182397 0.78 PIK3CD (0.63) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL182477 0.78 PIK3CD (0.63) CLK4PIK3CDPIK3CAPIK3CBPIK3CG
Hydrochloric Acid SCHEMBL3851637 0.77 ACVR1 (0.46) CLK4PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP claimed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US claimed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 EP claimed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO claimed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA CLK4 586/4885PIK3CD 6/4885PIK3CA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.